Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

Name: Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.
Published: 2026
License: Public Domain

Centre Antoine Lacassagne · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

immunotherapy pembrolizumab pharmacokinetics

non-small cell lung carcinoma (nsclc), metastatic head and neck squamous cell carcinoma, pembrolizumab, immunotherapy, salvage chemotherapy, pharmacokinetics, interventional, phase4

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

Related documents